Sitagliptin Phos/Metformin Hcl
Brand name: Janumet
Rank #58 of 500 drugs by total cost
$302.2M
Total Cost
329,315
Total Claims
$302.2M
Total Cost
13,179
Prescribers
$918
Cost per Claim
23,714
Beneficiaries
577,853
30-Day Fills
$23K
Avg Cost/Provider
25
Avg Claims/Provider
About Sitagliptin Phos/Metformin Hcl
Sitagliptin Phos/Metformin Hcl (sold as Janumet) was prescribed 329,315 times by 13,179 Medicare Part D providers in 2023, costing the program $302.2M. At $918 per claim, this is a high-cost medication.
Related Drugs by Cost
| # | Drug | Total Cost | Claims |
|---|---|---|---|
| 55 | Cariprazine Hcl (Vraylar) | $329.1M | 226,854 |
| 56 | Albuterol Sulfate (Albuterol Sulfate Hfa) | $312.2M | 7,904,120 |
| 57 | Rifaximin (Xifaxan) | $310.0M | 111,328 |
| 58 | Sitagliptin Phos/Metformin Hcl (Janumet) | $302.2M | 329,315 |
| 59 | Tofacitinib Citrate (Xeljanz Xr) | $294.4M | 49,478 |
| 60 | Umeclidinium Brm/Vilanterol Tr (Anoro Ellipta) | $294.3M | 480,651 |
| 61 | Gabapentin (Gabapentin) | $291.0M | 15,142,335 |
Data from CMS Medicare Part D Prescriber-Drug Public Use File, 2023. Methodology